OCT 31, 2018 09:02 AM PDT

Cytostatic Drug Proved Potent For Cancer

WRITTEN BY: Nouran Amin

Image via ArcoMed

A study published in journal Angewandte Chemie, describes how a cytostatic drug, consisting of therapeutically active molecules that is linked to specific antibodies can treat tumors. Such novel conjugates are made from antibodies and a protein that inhibits kinesin spindle formation.

The study revealed that changing the “linkage” between these two components allows for the drugs cytostatic activity in a broad palette of cancers.

The purpose of the study was to introduce a new cytostatic drug that will not produce adverse effects on cancer patients. This is especially true since many medications may be effective but interfere with physiological regulatory mechanisms that cause the impairment of immune defenses, produce hair loss, and induce nausea.

Watch the short video below on side-effects of chemotherapeutic drugs:

The study was aimed at introducing a cytostatic drug directly into tumor cells before triggering a toxic effect. One proposed way was to attach small drug molecules to an antibody (that binds to specific sites—antigens) and produce a conjugate.

The linker will serve as a bridging component that will hold the conjugate together for as long as it circulates in the blood. Although incorporating cytostatic drugs into antibody conjugates have been so far successful, they are limited.

Diverging away from the classic mechanisms of cytostatic drugs, researchers have opted to use cytotoxin that which that utilizes a different biological pathway. More specifically, the cytotoxin is a novel pyrrole-based kinesin spindle protein (KSP) inhibitor which is implicated centrosome separation during cell division. Low doses of this cytoxin is highly effective enough to inhibiting this step of the cell cycle leading to a strong antitumor effect. The researchers have demonstrated that use of this technique can produce a highly effective antibody conjugates that allow them to target a variety of tumor types.

Image Credit: Wiley Online Libraries

The developed conjugates were seen to be very potent in vitro and when using experiments on mice, the conjugates led to complete remission of a human bladder tumor model with minimal side effects

Source: Wiley

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
OCT 24, 2018
Drug Discovery
OCT 24, 2018
Peptide Ruptures Viral Membrane of Zika Virus
According to a recent study at Nanyang Technological University, Singapore (NTU Singapore), a newly engineered antiviral peptide will aim to attack the vir...
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Combination of Drugs Extends Lifespan of C. elegans
In a study published in the journal Developmental Cell, a cocktail of pharmaceutical drugs were recently found to extend the life of the microscopic worm,...
NOV 21, 2018
Microbiology
NOV 21, 2018
Human Antibody That can Neutralize West Nile Virus is Found
In 1999, there were 62 cases of West Nile Virus in New York State. Since then it has spread around the United States....
DEC 17, 2018
Health & Medicine
DEC 17, 2018
Microglial Priming And Pain
Microglia are in primed states when injury happens and acute exposure to opioids activates them further creating pain sensitivity....
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Buruli ulcer: promising drug for a forgotten disease
One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central...
Loading Comments...